12:00 AM
Jun 26, 2000
 |  BC Week In Review  |  Company News  |  Deals

OSI, Pfizer deal

OSIP received from partner PFE a royalty-free license to develop and market CP-358,774 ( OSI-774), a small molecule epidermal growth factor receptor ( EGFR) inhibitor in Phase...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >